Integrated data analysis pipeline for whole human genome transcription factor binding sites prediction

Transcription factors (TF) have a central role in regulating gene expression by binding to regulatory regions in DNA. Position weight matrix (PWM) model is the most commonly used model for representing and predicting TF binding sites. Consequently, several studies have been done on predicting TF binding sites using PWMs and many databases have been created containing large numbers of PWMs. However, these studies require the user to search for binding sites for each PWM separately, thus making it is difficult to get a general view of binding predictions for many PWMs simultaneously. In response to this need, this thesis project evaluates both individual and groups of PWMs and creates an effortless method to analyze and visualize the desired set of PWMs together, making it easier for biologist to analyze large amount of data in a short period of time. For this purpose, we used bioinformatics methods to detect putative TF binding sites in human genome and make them available online via the UCSC genome browser. Still, the sheer amount of data in PWM databases required a more efficient method to summarize TF binding prediction. Hence, we used PWM similarity measures and clustering algorithms to group together PWMs and to create one integrated database from four popular PWM databases: SELEX, TRANSFAC, UniPROBE, and JASPAR. All results are made publicly available for the research community via the UCSC genome broswer

Plasmids conferring resistance to extended-spectrum beta-lactamases including a rare IncN+IncR multireplicon carrying blaCTX-M-1 in Escherichia coli recovered from migrating barnacle geese (Branta leucopsis) [version 1; peer review: 2 approved]

Peer reviewe

Whole-Genome Sequencing of Extended-Spectrum Beta-Lactamase-Producing Escherichia coli From Human Infections in Finland Revealed Isolates Belonging to Internationally Successful ST131-C1-M27 Subclade but Distinct From Non-human Sources

Antimicrobial resistance (AMR) is a growing concern in public health, particularly for the clinically relevant extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacteriaceae. Studies describing ESBL-producing Escherichia coli clinical samples from Finland to the genomic level and investigation of possible zoonotic transmission routes are scarce. This study characterizes ESBL-producing E. coli from clinical samples in Finland using whole genome sequencing (WGS). Comparison is made between animal, food, and environmental sources in Finland to gain insight into potential zoonotic transmission routes and to recognize successful AMR genes, bacterial sequence types (STs), and plasmids. ESBL-producing E. coli isolates (n = 30) obtained from the Eastern Finland healthcare district between 2018 and 2020 underwent WGS and were compared to sequences from non-human and healthy human sources (n = 67) isolated in Finland between 2012 and 2018. A majority of the clinical isolates belonged to ST131 (n = 21; 70%), of which 19 represented O25:H4 and fimH30 allele, and 2 O16:H5 and fimH41 allele. Multidrug resistance was common, and the most common bla gene identified was bla(CTX-M-27) (n = 14; 47%) followed by bla(CTX-M-15) (n = 10; 33%). bla(CTX-M-27) was identified in 13 out of 21 isolates representing ST131, with 12 isolates belonging to a recently discovered international E. coli ST131 C1-M27 subclade. Isolates were found to be genetically distinct from non-human sources with core genome multilocus sequence typing based analysis. Most isolates (n = 26; 87%) possessed multiple replicons, with IncF family plasmids appearing in 27 (90%) and IncI1 in 5 (17%) isolates. IncF[F1:A2:B20] replicon was identified in 11, and IncF[F-:A2:B20] in 4 isolates. The results indicate the ST131-C1-M27 clade gaining prevalence in Europe and provide further evidence of the concerning spread of this globally successful pathogenic clonal group. This study is the first to describe ESBL-producing E. coli in human infections with WGS in Finland and provides important information on global level of the spread of ESBL-producing E. coli belonging to the C1-M27 subclade. The results will help guide public health actions and guide future research.Peer reviewe

Plasmid-Borne and Chromosomal ESBL/AmpC Genes in Escherichia coli and Klebsiella pneumoniae in Global Food Products

Plasmid-mediated extended-spectrum beta-lactamase (ESBL), AmpC, and carbapenemase producing Enterobacteriaceae, in particular Escherichia coli and Klebsiella pneumoniae, with potential zoonotic transmission routes, are one of the greatest threats to global health. The aim of this study was to investigate global food products as potential vehicles for ESBL/AmpC-producing bacteria and identify plasmids harboring resistance genes. We sampled 200 food products purchased from Finland capital region during fall 2018. Products originated from 35 countries from six continents and represented four food categories: vegetables (n = 60), fruits and berries (n = 50), meat (n = 60), and seafood (n = 30). Additionally, subsamples (n = 40) were taken from broiler meat. Samples were screened for ESBL/AmpC-producing Enterobacteriaceae and whole genome sequenced to identify resistance and virulence genes and sequence types (STs). To accurately identify plasmids harboring resistance and virulence genes, a hybrid sequence analysis combining long- and short-read sequencing was employed. Sequences were compared to previously published plasmids to identify potential epidemic plasmid types. Altogether, 14 out of 200 samples were positive for ESBL/AmpC-producing E. coli and/or K. pneumoniae. Positive samples were recovered from meat (18%; 11/60) and vegetables (5%; 3/60) but were not found from seafood or fruit. ESBL/AmpC-producing E. coli and/or K. pneumoniae was found in 90% (36/40) of broiler meat subsamples. Whole genome sequencing of selected isolates (n = 21) revealed a wide collection of STs, plasmid replicons, and genes conferring multidrug resistance. bla(CTX-M-15)-producing K. pneumoniae ST307 was identified in vegetable (n = 1) and meat (n = 1) samples. Successful IncFII plasmid type was recovered from vegetable and both IncFII and IncI1-I gamma types from meat samples. Hybrid sequence analysis also revealed chromosomally located beta-lactamase genes in two of the isolates and indicated similarity of food-derived plasmids to other livestock-associated sources and also to plasmids obtained from human clinical samples from various countries, such as IncI type plasmid harboring bla(TEM-52C) from a human urine sample obtained in the Netherlands which was highly similar to a plasmid obtained from broiler meat in this study. Results indicate certain foods contain bacteria with multidrug resistance and pose a possible risk to public health, emphasizing the importance of surveillance and the need for further studies on epidemiology of epidemic plasmids.Peer reviewe

lavalleelab/AMLclassifier: code updates

<p>Artificial Neural Network classifier for AML single cell RNA-seq data </p&gt

E2BMO: Facilitating User Interaction with a BioMimetic Ontology via Semantic Translation and Interface Design

Function is a key central concept to the practice of biomimicry. Many published models of the biomimicry process include steps to identify, understand, and translate function of biological systems. Examples include functional modeling, decomposition, or abstraction with tools specifically designed to facilitate such steps. A functional approach to biomimicry yields a semantic bridge between biology and engineering, enabling practitioners from a variety of backgrounds to more easily communicate and collaborate in a biomimicry design process. Although analysis of function is likely a necessary part of biomimicry design, recent work suggests it is not sufficient without a more systematic understanding of the complex biological context in which a function exists (e.g., scale and trade-offs). Consequently, emerging tools such as ontologies are being developed that attempt to capture the intricacies of biological systems (including functions), such as their complex environmental and behavioral interactions. However, due to the complexity of such tools, they may be under-utilized. Here, we propose a solution through a computer-aided user interface tool which integrates a biomimetic ontology with a thesaurus-based functional approach to biomimicry. Through a proof of concept illustrative case study, we demonstrate how merging existing tools can facilitate the biomimicry process in a systematic and collaborative way, broadening solution discovery. This work offers an approach to making existing tools, specifically the BioMimetic Ontology, more accessible and encompassing of different perspectives via semantic translation and interface design. This provides the user with the opportunity to interface and extract information from both the Engineering-to-Biology Thesaurus and the BioMimetic Ontology in a way that was not possible before. The proposed E2BMO tool not only increases the accessibility of the BioMimetic Ontology, which ultimately aims to streamline engineers’ interaction with the bio-inspired design process, but also provides an option for practitioners to traverse biological knowledge along the way, encouraging greater interdisciplinary collaboration and consideration when conducting biomimicry research

Immunotherapeutic targeting of surfaceome heterogeneity in AML

Summary: Immunotherapy remains underexploited in acute myeloid leukemia (AML) compared to other hematological malignancies. Currently, gemtuzumab ozogamicin is the only therapeutic antibody approved for this disease. Here, to identify potential targets for immunotherapeutic intervention, we analyze the surface proteome of 100 genetically diverse primary human AML specimens for the identification of cell surface proteins and conduct single-cell transcriptome analyses on a subset of these specimens to assess antigen expression at the sub-population level. Through this comprehensive effort, we successfully identify numerous antigens and markers preferentially expressed by primitive AML cells. Many identified antigens are targeted by therapeutic antibodies currently under clinical evaluation for various cancer types, highlighting the potential therapeutic value of the approach. Importantly, this initiative uncovers AML heterogeneity at the surfaceome level, identifies several antigens and potential primitive cell markers characterizing AML subgroups, and positions immunotherapy as a promising approach to target AML subgroup specificities

CBFA2T3::GLIS2 Pediatric Acute Megakaryoblastic Leukemia is Sensitive to BCL-XL Inhibition by Navitoclax and DT2216.

Acute megakaryoblastic leukemia (AMKL) is a rare, developmentally restricted and highly lethal cancer of early childhood. The paucity and hypocellularity (due to myelofibrosis) of primary patient samples hamper the discovery of cell- and genotype-specific treatments. AMKL is driven by mutually exclusive chimeric fusion oncogenes in two thirds of cases, with CBFA2T3::GLIS2 (CG2) and NUP98 fusions (NUP98r) representing the highest fatality subgroups. We established CD34+ cord blood-derived CG2 models (n=6) that sustain serial transplantation and recapitulate human leukemia regarding immunophenotype, leukemia initiating cell frequencies, co-mutational landscape and gene expression signature with distinct upregulation of the pro-survival factor BCL2. Cell membrane proteomic analyses highlighted CG2 surface markers preferentially expressed on leukemic cells compared to CD34+ cells (e.g. NCAM1, CD151). AMKL differentiation block in the mega-erythroid progenitor space was confirmed by single cell profiling. While CG2 cells were rather resistant to BCL2 genetic knockdown or selective pharmacological inhibition with Venetoclax, they were vulnerable to strategies that target the megakaryocytic pro-survival factor BCL-XL (BCL2L1), including in vitro and in vivo treatment with BCL2/BCL-XL/BCL-W inhibitor Navitoclax and DT2216, a selective BCL-XL PROTAC (proteolysis-targeting chimera) degrader developed to limit thrombocytopenia in patients. NUP98r AMKL were also sensitive to BCL-XL inhibition, but not the NUP98r monocytic leukemia, pointing to a lineage-specific dependency. Navitoclax or DT2216 treatment in combination with low dose cytarabine further reduced leukemic burden in mice. This work extends the cellular and molecular diversity set of human AMKL models and uncovers BCL-XL as a therapeutic vulnerability in CG2 and NUP98r AMKL